Nuvilex Describes Critical Advantages of Live-Cell Encapsulation Technology

SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB: NVLX) described today some of the characteristics and benefits of using the live-cell encapsulation technology that is the basis of the Company’s recently-acquired pancreatic cancer treatment.

The beads are made of natural cotton, modified to produce final beads with cells inside, and referred to as such due to their physically round characteristic. Overall, beads are about the size of the head of a pin and can contain many cells after packaging. They have been tested and shown to be safe for use in animals and humans. In addition, they did not cause responses by the body’s immune system to attack or eliminate them. As a result, any cell type could be implanted in the body without need for administration of any drugs that decrease the body’s immune response. This is important for potential therapies and will dramatically increase versatility and value of this technology into the future.

The encapsulated cells act as “mini-factories” and can carry out specific functions like activating cancer drugs. In the case of the recently acquired pancreatic cancer treatment, the cells converted the “inactive” cancer drug ifosfamide into its cancer-killing form. The porous nature of the beads allowed nutrients to enter and support the health of the encapsulated cells. In addition, beads are porous enough to permit activated drugs or other biological substances to leave and provide benefit to their surrounding environment.

In general, beads provide a healthy home for the live cells. It also allows them to remain alive for extended periods of time and make active drug for as long as needed. In the pancreatic cancer clinical trials, the beads and the cells inside them, were still present in patients without change to either even after two years. It is likely these packaged cells could at a future time be used again to fight a tumor that re-grows.

An additional asset with this technology noted during preclinical studies and confirmed in the pancreatic cancer clinical trial is that the beads remain in the location they have been placed and don’t move away. This property helps to ensure delivery of the chemotherapy drug directly to the tumor and their potential future use if such need should arise.

Dr. Robert F. Ryan, Corporate Executive of Nuvilex relayed, “The benefits of this cell encapsulation are extensive. In the case of our pancreatic cancer treatment, not only can we maximize the cancer drug’s effectiveness against the tumors, but also decrease the drug’s side effects and in the future possibly be able to retreat a pancreatic cancer patient if they exhibit a recurrence by simply giving the patient chemotherapy again to extend their lifespan even further. These factors, in combination with the absence of an immune response to the beads or cells inside them make this cell encapsulation technology a perfect delivery vehicle for tumor-site-specific pancreatic cancer therapy.”

Nuvilex is:

a Green Company believing in “Good for You, Good for the Environment.” We continue to make an extensive effort toward completing our company’s paradigm shift and expand our natural product lines while making important strides in biotechnology. Our pancreatic cancer treatment utilizes live encapsulated cells, has completed a Phase II clinical trial and is being grown and developed further. Other natural product, biotechnology and clinical advances are being pursued and will be evident shortly. Nuvilex’s newly launched site at www.nuvilex.com, is being expanded daily and provides information, directions for purchase directly from the website, and provides specifics for Investors and Shareholders as well, with even more changes planned. Current Nuvilex products include Gluten-Free Cinnergen™, Cinnechol™, and Cinnsational™ to enhance a healthy lifestyle; Talsyn™ and NumaDerm™ for cosmetic use; Reme-Flu™, Legacy Biotechnologies’ flu combating regimen; Virgin® and Infinitink®, heavy-metal-free tattoo inks. Additional developments are ongoing for Citroxin™ and Oraphyte™, Nuvilex’s antimicrobial and antinematodal agents.

Safe Harbor Statement

This information may contain forward-looking statements involving risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes including product demand, market competition, and Nuvilex’s ability to meet current or future plans. Readers or Investors should study and understand all risks before making investment decisions and are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.



CONTACT:

Investor Relations Contact:
Marmel Communications, LLC
Marlin Molinaro, 702-434-8692
[email protected]

KEYWORDS:   United States  North America  Arizona  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.